An observational study in Acute Ischemic Stroke and Active Cancer, sponsored by Osaka University. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Osaka University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Ischemic Stroke with a site in Japan — 7 open to participants now, 11 under way, 3 of them phase 3. Ischemic Stroke · Japan.
Among the 43 studies in Ischemic Stroke with a site in Japan, this one is one of 3 that started in 2026, is one of 8 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 43rd registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →7 of the 43 studies in Ischemic Stroke with a site in Japan are open now. Recruiting first, the newest first:
Takeda · Sites in Japan, United States, Belgium and 7 more countries
Ages 18+
Astellas Pharma Inc · Sites in Japan
Ages 18–80
Hyogo Medical University · Sites in Japan, Thailand, Vietnam
Ages 18–84
Nippon Medical School · Sites in Japan
Ages 18+
Corxel Pharmaceuticals · Sites in Japan, United States, Belgium and 18 more countries
Ages 18–90
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 10 · Phase 4 5
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 300 across 773 observational studies indexed under Ischemic Stroke.
Median enrollment 270 across the 35 interventional studies, 650 across the 8 observational. Of the 28 that completed or were terminated, 10 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 43 have an industry lead sponsor. The 10 most frequent:
Osaka University is the lead sponsor of 34 studies on the registry; 4 are open to participants now.
Osaka University has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies in Ischemic Stroke with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02251665National Cerebral and Cardiovascular Center, JapanNational Cerebral and Cardiovascular Center (NCVC) Stroke Registry | 2027-03 |
| NCT07819526Osaka UniversityAcute Ischemic Stroke in Patients With Active Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Ischemic Stroke with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this multicenter prospective observational study, conducted at 24 hospitals in Japan, is to learn about recurrent ischemic stroke in people with active cancer who develop acute ischemic stroke. One of the main objectives is to evaluate how often ischemic stroke recurs during follow-up.
The main questions this study aims to answer are:
Participants will receive medical care determined by their treating physicians. Researchers will collect information about participants' cancer, stroke characteristics, test results, treatments, recurrent ischemic stroke, and other clinical outcomes. Researchers will also explore whether clinical factors are associated with recurrent ischemic stroke and other outcomes. This study will not assign participants to a specific treatment.
The study population will consist of participants with acute ischemic stroke and active cancer who receive medical care at participating hospitals in Japan. Eligible participants will be enrolled prospectively during the study enrollment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with active cancer who develop acute ischemic stroke and are enrolled prospectively at participating hospitals. Clinical information, treatments, recurrent ischemic stroke, and other outcomes will be collected during follow-up.
Percentage of Participants With Recurrent Ischemic Stroke Within 3 Months
The percentage of participants who experience recurrent ischemic stroke during follow-up. Recurrent ischemic stroke will be determined according to the criteria prespecified in the study protocol.
Time frame: From enrollment through 3 months of follow-up
Plan to share: No — Individual participant data will not be shared because no data-sharing plan has been established for this study. Study findings will be reported only in aggregate form.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.
Of 397 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 15 months is below that.
Counting every sponsor, half of 439 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osaka University